Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 4/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | PRKCA | P17252 | 2/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12662478 | 0.94 | FAAH (0.40) | FAAHPTGESWDR5FLT3PIK3C2B | |
| SCHEMBL12662378 | 0.92 | PTGES (0.44) | PTGESFLT3GSK3BPIK3C2B | |
| SCHEMBL12662402 | 0.90 | PTGES (0.42) | PTGESWDR5FLT3PRKCAPRKCQ | |
| SCHEMBL12662579 | 0.89 | FAAH (0.39) | FAAHWDR5 | |
| SCHEMBL12662398 | 0.88 | PTGES (0.43) | PTGESFLT3PIK3C2B | |
| SCHEMBL12662551 | 0.87 | FAAH (0.41) | FAAHWDR5 | |
| SCHEMBL12662403 | 0.86 | PTGES (0.45) | PTGESFLT3GSK3B | |
| SCHEMBL12662476 | 0.84 | PTGES (0.42) | PTGESWDR5FLT3 | |
| SCHEMBL12662400 | 0.83 | LMNA (0.45) | PTGESWDR5FLT3 | |
| SCHEMBL12662057 | 0.83 | PARP1 (0.48) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315763-B1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | FAAH 2426/4885PTGES 1022/4885WDR5 556/4885 |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | FAAH 1840/4885PTGES 1594/4885WDR5 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.